Table 1. Patient demographics and disease characteristics.
| Abbreviated trastuzumab (N=115) | Conventional trastuzumab (N=112) | |
|---|---|---|
|
Race – no. (%) | ||
| White | 106 (92) | 97 (87) |
| Hispanic | 2 (2) | 3 (3) |
| Black | 4 (3.5) | 9 (8) |
| Other | 3 (2.5) | 3 (2) |
|
Age (years) – no. (%) | ||
| <40 | 21 (18) | 21 (19) |
| ⩾40 | 94 (82) | 91 (81) |
| Age – median (range) | 49 (26–78) | 48 (22–76) |
|
Nodal status – no. (%) | ||
| 1–3 positive nodes | 58 (51) | 64 (57) |
| 4–9 positive nodes | 35 (30) | 32 (29) |
| ⩾10 positive nodes | 22 (19) | 16 (14) |
| Number of positive nodes – median (range) | 3 (1–29) | 3 (1–24) |
|
ER/PgR status – no. (%) | ||
| ER−/PgR− | 45 (39) | 41 (37) |
| ER−/PgR+ | 6 (5) | 5 (14) |
| ER+/PgR− | 9 (9) | 16 (4) |
| ER+/PgR+ | 54 (47) | 50 (45) |
| Missing | 1 (1) | 0 (0) |
|
ECOG performance status – no. (%) | ||
| 0 | 100 (87) | 99 (88) |
| 1 | 14 (12) | 12 (11) |
| 2 | 1 (1) | 1 (1) |
|
Most extensive surgery – no. (%) | ||
| Less than mastectomy | 32 (28) | 41 (36) |
| Modified radical mastectomy | 70 (61) | 59 (53) |
| Total (simple) mastectomy | 13 (11) | 12 (11) |